Myelodysplastic Syndromes
July 2019 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: A systematic review.
Authors:Affentranger L, Bohlius J, Hallal M, Bonadies N
Institution:Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Switzerland. University Hospital, University of Bern, Switzerland; Department for BioMedical Research, University of Bern, Switzerland. University Hospital, University of Bern, Switzerland; Department for BioMedical Research, University of Bern, Switzerland. Electronic address: Nicolas.Bonadies@insel.ch.
Journal:Crit Rev Oncol Hematol. 2019 Apr;136:37-47. doi: 10.1016/j.critrevonc.2019.01.021. Epub 2019 Feb 15.

2:Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome.
Authors:Itonaga H, Ishiyama K, Aoki K, Aoki J, Ishikawa T, Uchida N, Ohashi K, Ueda Y, Fukuda T, Sakura T, Ohno Y, Iwato K, Okumura H, Kondo T, Ichinohe T, Takanashi M, Atsuta Y, Miyazaki Y
Institution:Department of Hematology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, Japan. itonaga-ngs@umin.ac.jp.; Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan.; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.; Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Journal:Ann Hematol. 2019 Jun;98(6):1367-1381. doi: 10.1007/s00277-019-03653-7. Epub 2019 Mar 11.

3:Glasdegib: First Global Approval.
Authors:Hoy SM
Institution:Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Journal:Drugs. 2019 Feb;79(2):207-213. doi: 10.1007/s40265-018-1047-7.

4:Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
Authors:Tang Y, Miao M, Han S, Qi J, Wang H, Ruan C, Wu D, Han Y
Institution:Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Collaborative Innovation Center of Hematology of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China. Electronic address: wudepei@medmail.com.cn.; Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Collaborative Innovation Center of Hematology of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China. Electronic address: hanyue@suda.edu.cn.
Journal:Crit Rev Oncol Hematol. 2019 Jan;133:74-83. doi: 10.1016/j.critrevonc.2018.07.013. Epub 2018 Aug 3.

5:Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.
Authors:Lee JH, List A, Sallman DA
Institution:University of South Florida Morsani College of Medicine, Tampa, Florida. Institute, Tampa, Florida. Institute, Tampa, Florida.
Journal:Eur J Haematol. 2019 Mar;102(3):203-209. doi: 10.1111/ejh.13207. Epub 2019 Jan 16.

6:Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.
Authors:Schetelig J, de Wreede LC, van Gelder M, Koster L, Finke J, Niederwieser D, Beelen D, Mufti GJ, Platzbecker U, Ganser A, Heidenreich S, Maertens J, Socie G, Brecht A, Stelljes M, Kobbe G, Volin L, Nagler A, Vitek A, Luft T, Ljungman P, Yakoub-Agha I, Robin M, Kroger N
Institution:Universitaetsklinikum Dresden, Dresden, Germany. Johannes.Schetelig@uniklinikum-dresden.de. Johannes.Schetelig@uniklinikum-dresden.de.
Journal:Leukemia. 2019 Mar;33(3):686-695. doi: 10.1038/s41375-018-0302-y. Epub 2018 Dec 20.

7:The current approach to the diagnosis of myelodysplastic syndromes().
Authors:Weinberg OK, Hasserjian RP
Institution:Department of Pathology, Boston Children's Hospital, Boston, MA, USA. Electronic address: Olga.weinberg@childrens.harvard.edu.
Journal:Semin Hematol. 2019 Jan;56(1):15-21. doi: 10.1053/j.seminhematol.2018.05.015. Epub 2018 Jun 23.

8:Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan.
Authors:Ko BS, Chang MC, Chiou TJ, Chang TK, Chen YC, Lin SF, Chang CS, Lu YC, Yeh SP, Chen TY, Hwang WS
Institution:a Department of Internal Medicine , National Taiwan University Hospital , Taipei , Taiwan. Taiwan. General Hospital , Taipei , Taiwan. Taiwan. Taiwan. University Hospital , Kaohsiung , Taiwan. Taiwan. Tainan , Taiwan. Taichung , Taiwan.
Journal:Hematology. 2019 Dec;24(1):247-254. doi: 10.1080/16078454.2018.1557860.

9:Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Authors:Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, Pollyea DA, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M
Institution:Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA. jcortes@mdanderson.org. Gdansk, Poland. Hamburg, Germany.
Journal:Leukemia. 2019 Feb;33(2):379-389. doi: 10.1038/s41375-018-0312-9. Epub 2018 Dec 16.

10:Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Authors:Liu Y, Bewersdorf JP, Stahl M, Zeidan AM
Institution:Department of Internal Medicine, Section of Hematology, Yale University School of Medicine, New Haven, CT, USA. Medicine, New Haven, CT, USA. Cancer Center, New York, NY, USA. Medicine, New Haven, CT, USA. Electronic address: amer.zeidan@yale.edu.
Journal:Blood Rev. 2019 Mar;34:67-83. doi: 10.1016/j.blre.2018.12.001. Epub 2018 Dec 5.

11:Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations.
Authors:Girmenia C, Candoni A, Delia M, Latagliata R, Molteni A, Oliva EN, Palumbo GA, Poloni A, Salutari P, Santini V, Voso MT, Musto P
Institution:Dipartimento di Ematologia, Oncologia e Dermatologia, Policlinico Umberto I, Sapienza University of Rome, Italy. Electronic address: girmenia@bce.uniroma1.it.; Clinica Ematologica, Centro Trapianti e Terapie Cellulari, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy.; Hematology and BMT Unit, Policlinic of Bari, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.; Unita Complessa di Ematologia, ASST Cremona, Cremona, Italy.; Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy.
Journal:Blood Rev. 2019 Mar;34:16-25. doi: 10.1016/j.blre.2018.10.002. Epub 2018 Oct 28.

12:Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes.
Authors:Zeidan AM, Giri S, DeVeaux M, Ballas SK, Duong VH
Institution:Yale University School of Medicine and Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven, New Haven, CT, USA. amer.zeidan@yale.edu. at Yale New Haven, New Haven, CT, USA. Philadelphia, PA, USA.
Journal:Ann Hematol. 2019 Feb;98(2):339-350. doi: 10.1007/s00277-018-3539-7. Epub 2018 Nov 9.

13:Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review.
Authors:Seguier J, Gelsi-Boyer V, Ebbo M, Hamidou Z, Charbonnier A, Bernit E, Durand JM, Harle JR, Vey N, Schleinitz N
Institution:Aix-Marseille Univ, APHM, Medecine Interne Hopital de la Timone, Marseille, France. France. France. France. France. France. France. France. France. Electronic address: nicolas.schleinitz@ap-hm.fr.
Journal:Autoimmun Rev. 2019 Jan;18(1):36-42. doi: 10.1016/j.autrev.2018.07.009. Epub 2018 Nov 5.

14:Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy.
Authors:Alkharabsheh OA, Saadeh SS, Zblewski DL, Gangat N, Begna KH, Elliott MA, Alkhateeb HB, Patnaik MS, Hogan WJ, Litzow MR, Al-Kali A
Institution:Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. alkali.aref@mayo.edu.
Journal:Ann Hematol. 2019 Feb;98(2):331-337. doi: 10.1007/s00277-018-3509-0. Epub 2018 Oct 18.

15:Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.
Authors:Othus M, Sekeres MA, Nand S, Garcia-Manero G, Appelbaum FR, Erba HP, Estey E
Institution:Fred Hutchinson Cancer Research Center, Seattle, WA, USA. mothus@fredhutch.org.
Journal:Leukemia. 2019 Feb;33(2):371-378. doi: 10.1038/s41375-018-0275-x. Epub 2018 Oct 12.

16:Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it.
Authors:Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X
Institution:Section of Hematology, Division of Hematology/Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, USA; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, USA. Electronic address: amer.zeidan@yale.edu. Medicine, Yale University School of Medicine, New Haven, USA. University, New Haven, USA; Department of Chronic Disease Epidemiology, School of Public Health, Yale University, New Haven, USA. University, New Haven, USA; Department of Health Policy and Management, School of Public Health, Yale University, New Haven, USA. University, New Haven, USA; Department of Chronic Disease Epidemiology, School of Public Health, Yale University, New Haven, USA.
Journal:Blood Rev. 2019 Mar;34:1-15. doi: 10.1016/j.blre.2018.09.001. Epub 2018 Sep 21.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount


Medifocus Guidebook on Myelodysplastic Syndromes

Updated: July 5, 2019
184 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MS93437716

Coupon Expires: August 22, 2019



What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
P.M.
Saint Ismier, France


"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
S.M.
Rockville, Maryland


"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
N.M.
Los Angeles, California



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2019 Medifocus, Inc. All rights reserved.